Effect of aprotinin on endothelial cell activation

Journal of Thoracic and Cardiovascular Surgery

Volumn 122, Issue 1, 2001, Pages 123-128

  Asimakopoulos, George ^a   Lidington, Elaine A ^b   Mason, Justin ^b   Haskard, Dorian O ^b   Taylor, Kenneth M ^a   Landis, R Clive ^b,c  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOPULMONARY BYPASS; CELL ACTIVATION; CELL MIGRATION; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LEUKOCYTE; NEUTROPHIL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VASCULAR ENDOTHELIUM;

EID: 18744362417     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1067/mtc.2001.114356     Document Type: Article

References (31)

1. Boyle EM Jr, Pohlman TH, Johnson MC, Verrier ED. The systemic inflammatory response. Ann Thorac Surg. 1997:64:S31-7.
2. Taylor KM. SIRS: The systemic inflammatory response syndrome after cardiac operations. Ann Thorac Surg. 1996:61:1607-8.
3. Gott JP Cooper WA, Schmidt FE, Brown WM 3rd. Wright CE. Merlino JD, et al. Modifying risk for extracorporeal circulation: Trial of four anti-inflammatory strategies. Ann Thorac Surg. 1998;66:747-53.
4. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-8.
5. Lahat N, Zlotnick AY, Shtiller R, Bar I. Merin G, Serum levels of IL-1, IL-6 and tumour necrosis factor in patients undergoing coronary artery bypass grafts or cholecystectomy. Clin Exp Immunol. 1992;89:255-60.
6. Butler J, Parker D, Pillai R, Westaby S, Shale DJ, Rocker GM. Effects of cardiopulmonary bypass on systemic release of neutrophil elastase and tumour necrosis factor. J Thorac Cardiovasc Surg. 1993;105:25-30.
7. Fujiwara T, Seo N, Murayama T, Hirata S, Kawahito K, Kawakami M. Transient rise in serum cytokines during coronary artery bypass graft surgery. Eur Cytokine Netw. 1997;8:61-6.
8. Asimakopoulos G, Smith PL, Ratnatunga CP, Taylor KM. Lung injury and acute respiratory distress syndrome after cardiopulmonary bypass. Ann Thorac Surg. 1999;68:1107-15.
9. Carlos TM, Harlan JM. Leukocyte-endothelial cell adhesion molecules. Blood. 1994;84:2068-101.
10. Bianchi E, Bender JR, Blasi F, Pardi R, Through and beyond the wall: Late steps in leukocyte transcndothelial migration. Immunol Today. 1997;18:586-91.
11. Hill GE, Alonso A, Spurzem JR, Stammers AH, Robbins RA. Aprotinin and methylprednisolone equally blunt neutrophil cardiopulmonary bypass-induced inflammation in humans. J Thorac Cardiovasc Surg. 1995;110:1658-62.
12. Alonso A, Witten CW, Hill GE. Pump prime only aprotinin inhibits cardiopulmonary bypass-induced neutrophil CDIIb up-regulation. Ann Thorac Surg. 2000;67:392-5.
13. Asimakopoulos G, Kohn A, Stefanou DC, Haskard DO, Landis RC, Taylor KM. Leukocyte integrin expression in patients undergoing cardiopulmonary bypass. Ann Thorac Surg. 2000;69:1192-7.
14. Hill GE, Pohorecki R, Alonso A, Rennard SI, Robbins RA. Aprotinin reduces interleukin-8 production and lung neutrophil accumulation after cardiopulmonary bypass. Anesth Analg. 1996;83:696-700.
15. Diego RP, Mihalakakos PJ, Hexum TD, Hill GE. Methylprednisolone and full-dose apotinin reduce reperfusion injury after cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 1997;11:29-31.
16. Wachffogel YT, Kucich U, Hack CE, Gluszko P, Niewiarowski S, Colman RW, et al. Aprotinin inhibits the contact, neutrophil, platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg. 1993;106:1-10.
17. Asimakopoulos G, Haskard DO, Taylor KM, Landis RC. Inhibition of neutrophil L-selectin shedding: A potential anti-inflammatory effect of aprotinin. Perfusion. 2000;15:495-9.
18. Asimakopoulos G, Thompson R, Nourshargh S, Lidington EA, Mason JC, Ratnatunga CP. et al. An anti-inflammatory property of aprotinin discovered at the level of leukocyte extravasation. J Thorac Cardiovasc Surg. 2000;120:361-9.
19. Jorens PG, Van Damme J, De Backer W, Bossaert L, De Jongh RF, Herman AG, et al. Interleukin-8 in the bronchoalveolar lavage fluid from patients with the adult respiratory distress syndrome (ARDS) and patients at risk for ARDS. Cytokine. 1992;4:592-7.
20. Miotla JM, Jeffery PK, Hellewell PG. Platelet-activating factor plays a pivotal role in the induction of experimental lung injury. Am J Respir Cell Mol Biol. 1998:18:197-204.
21. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev. 1990;0:427-51.
22. Wellicome SM, Thornhill MH, Pitzalis C, Thomas DS, Lanchbury JSS, Panayi GS. et al. A monoclonal antibody that detects a nivel antigen on endothelial cells that is induced by tumour necrosis factor, IL-1 or lipopolysaccharide. J Immunol. 1990;144:2558-65.
23. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G. A mechanism for the antiinflammatory effects of corticosteroids: The glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci U S A. 1992; 89: 9991-5.
24. Smith CW, Rothlein R, Hughes BJ, Mariscalo MM, Rudloff HE, Schmalstieg FC, et al. Recognition of an endothelial determinant for CD8-dependent human neutrophil adherence and transendothelial migration. J Clin Invest. 1988;82:1746-56.
25. Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci U S A. 1999:96:11023-7.
26. Poullis M, Manning R, Laffan M, Haskard DO, Taylor KM, Landis RC. The anti-thrombotic effect of aprotinin: Actions mediated through the protease-activated receptor I. J Thorac Cardiovasc Surg. 2000;120:370-8.
27. Molino M, Woolkalis MJ, Reavey-Cantwell J, Pratico D, Andrade-Gordon P, Barnathan ES, et al. Endothelial cell thrombin receptors and PAR-2: Two protease-activated receptors located in a single cellular environment. J Biol Chem. 1997;272:11133-41.
28. Pintigny D, Prigent DJ. Aprotinin can inhibit the proteolytic activity of thrombin: A fluorescent and enzymatic study. Eur J Biochem. 1992;207:89-95.
29. Kunitz M, Northrop JH. Isolation from beef pancreas of crystalline trypsinogen, trypsin, a trypsin inhibitor, and inhibitor trypsin compound. J Gen Physiol. 1936;19:991.
30. O'Brien PJ, Prevost N, Molino M, Hollinger MK, Woolkalis MJ, Woulfe DS, et al. Thrombin responses in human endothelial cells: Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PARI. J Biol Chem. 2000:275:13502-9.
31. Kaplanski G, Matin V, Fabrigoule M, Boulay V, Benoliel AM, Bongrand P, et al. Thrombin-activated human endothelial cells support monocyte adhesion in vitro following expression of intercellular adhesion molecule-1 (ICAM-1]; CD54) and vascular cell adhesion molecule-1 (VCAM-I; CD106). Blood. 1998;92:1259-67.